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Introduction
Several recent studies have sought to characterize biomarkers1–3 and 
clinical features4–6 that identify patients with cystic fibrosis (CF) 
who are at increased risk of antibiotic treatment. In all of these 
investigations, the need for antibiotics because of worsened health 
status was taken as evidence of pulmonary exacerbation (PEx). In lieu 
of a widely accepted definition for PEx,7,8 linking this phenomenon 
to clinical judgment is reasonable but inherently fosters variability in 
care delivery,9 and perhaps by extension, heterogeneous treatment 
outcomes. Because the morbidity associated with PEx is substantial 
and sometimes permanent,10–12 salubrious interventions should be 
timely, customized, and as efficacious as possible. Biomarkers are 
intended to facilitate the achievement of these goals, but a biomarker 
needs to not only reflect biologically informative processes predictive 
of PEx but also be suitable for use as a routine diagnostic tool.13 
Presently, most blood and sputum biomarker candidates do not 
satisfy the latter criterion and/or have not been validated by testing 
their performance in large cohorts.14
Our group has observed distinctive changes in measures 
of iron homeostasis during PEx.15 Treating CF patients with 
intravenous antibiotics for PEx significantly increased mean blood 
concentrations of iron but not hemoglobin while reducing serum 
levels of interleukin-6 (IL-6) and hepcidin-25, two mediators that 
lower blood iron content. IL-6 stimulates the liver to elaborate 
a small peptide called hepcidin-25 into the circulation16 that 
promotes iron sequestration by mononuclear cells17 and decreases 
iron uptake by enterocytes in the duodenum.18 Thus, antibiotics 
improve blood iron levels in the context of PEx by modulating the 
hormonal axis that couples inflammatory pathways (IL-6) to iron 
absorption and utilization (hepcidin-25). We have also reported19 
that serum levels of hepcidin-25 are closely correlated with Akron 
Pulmonary Exacerbation Score, an inventory of signs, symptoms, 
and diagnostic test results that has been used to standardize 
antibiotic prescription in an academic pulmonary practice.20
Like other CF biomarker candidates,1–3 serum hepcidin-25 is 
not yet available as a routine clinical laboratory test. However, given 
the aforementioned evidence that hepcidin-25 is elevated above 
baseline in patients during PEx and that its major physiological 
function is to lower serum iron levels,21 we questioned in this 
retrospective study whether a single measurement of serum iron, 
which is available to most clinicians within a few hours from any 
modern clinical laboratory, was associated with the time it took 
for patients to subsequently experience a PEx, defined as any need 
for oral or intravenous ABX. We also examined whether other 
biochemical, clinical, and microbiological variables obtained 
concurrently with the serum iron readings could be used to 
explain variation in time to ABX.
Methods
Spirometry, phlebotomy, and sputum cultures were performed 
at a single office visit in 54 CF adults who had participated in 
studies of iron homeostasis.15,22 Most of the subjects (n = 42) 
had no evidence of recently worsened health, and the rest 
(n = 12) were evaluated at the end of PEx treatment. Only data 
collected at a single office visit were analyzed. No information 
was censored because a subject failed to receive antibiotics after 
a specific time period; in other words, every subject considered 
in this study was treated with systemic (i.e., oral or intravenous) 
ABX at some point after the aforementioned testing. Permission 
to use these data was granted by the Committee for the Protection 
of Human Subjects at Dartmouth College (CPHS #23311). Serum 
iron readings, complete blood counts, and sputum cultures with 
in vitro ABX susceptibility profiles were obtained, as previously 
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reported.15,22 Data for each subject were included only if the most 
proximate date of ABX prescription after data acquisition was 
accurately identified in our electronic medical record (e-DH). This 
interval, measured in days, represented the time to ABX and was 
ascertained by reviewing notes and prescription orders for the 54 
subjects, all of whom were followed exclusively at our CF center.
JMP 11.2.1 (SAS Institute, Inc., Cary, NC) was used to perform 
all calculations and to create the plots in Figure 1. Subjects were 
categorized by the presence or absence of attributes listed in Table 1. 
Then, based on these distinctions, mean differences between 
subgroups in the number of days that had elapsed between data 
collection and ABX were compared by unpaired Student’s t-tests. 
For these univariate calculations, standard deviations (SD), 95% 
confidence intervals (CI) in the mean difference in time to ABX, 
and two-tailed p-values are given in Table 1. In Figure 1, simple 
linear regression was used to describe the relationships between 
serum iron and time to ABX (Figure 1A) and age and time to ABX 
(Figure 1B). Fisher’s exact test was used to compare proportions 
of subjects with and without categorical features.
Multivariate linear regression was used to identify specific 
attributes that significantly predicted variation in the number of 
days between identification of these attributes and ABX. Model 1 
(Table 2) included covariates listed in Table 1 that satisfied a 
p-value threshold of 0.25 for entry into and 0.10 for exclusion 
from the model. Model 2 employed forward stepwise entry of 
Aspergillus sputum status as a covariate into model 1. In model 
3, serum iron was entered as a covariate to model 2. The same 
p-value thresholds for inclusion and exclusion were used in 
models 2 and 3. A two-tailed p-value < 0.05 was considered 
statistically significant for all calculations.
Results
Subjects were similar to the general CF population
Clinical, biochemical, and microbiological attributes of the 
population are listed in Table 1. We observed a relatively even 
distribution of patients based on sex, homozygous F508del-
CFTR mutation status, and CF-related diabetes (CFRD). The 
proportions of subjects in our study who were homozygous for the 
F508del-CFTR mutation (56%) and carried a diagnosis of CFRD 
(55%) were similar to those seen in larger CF cohorts.23,24 On 
average, subjects had measurements of percent-predicted forced 
expiratory volume in 1 second (FEV1%) that were typical for most 
CF patients in this age range.25,26 The proportion of Aspergillus-
positive sputum cultures (29%) in our study was identical to that 
reported in another single-center investigation.27 Subjects with 
multidrug-resistant Pseudomonas aeruginosa (MDRPA) had a 
mean serum iron level (42.5 mcg/dL) that was similar to that of 
uninfected subjects (48.8 mcg/dL).
Sputum Aspergillus and CFRD were associated with shorter 
time to ABX
Of the categorical distinctions in Table 1, only isolation of 
Aspergillus species from a sputum culture sent to the microbiology 
laboratory at the time of serum iron measurement and having 
a diagnosis of CFRD at the time of serum iron measurement 
were associated with a shorter time to ABX. Subjects with CFRD 
received ABX an average of 67.1 days sooner than those without 
CFRD. Subjects with Aspergillus-positive sputum cultures received 
ABX an average of 64.9 days earlier than those without Aspergillus 
infection. Fisher’s exact test revealed that subjects with Aspergillus 
were not significantly more likely to have CFRD (odds ratio = 3.3, 
95% CI 0.9, 12.2, p = 0.08). F508del-CFTR homozygosity, female 
sex, FEV1%, and methicillin-resistant Staphylococcus aureus 
(MRSA) or MDRPA in sputum culture were not associated with 
differences in time to ABX. Importantly, these were univariate 
comparisons that did not address the issue of multiple factors 
being present in the same subject.
Serum iron and age are associated with time to ABX
We observed linear relationships between serum iron and 
time to ABX and between age and time to ABX (Figure 1). The 
relationship between serum iron and time to ABX (Panel A) can 
be expressed by the function, time to ABX = 1.34(serum iron) + 
53.6. The correlation coefficient, r, for the fit line was 0.39 (p = 
0.004). In Panel B, time to ABX = 6.1(age) – 60.2 with r = 0.44 
(p = 0.0008). Serum iron and age were not correlated with each 
other (r = −0.0003, p = 0.99).
Figure 1. Linear regression models depicting the relationships between (A) time to ABX and serum iron and (B) time to ABX and age. Shaded regions represent the 95% 
CI for the best fit lines.
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Serum iron, age, and sputum Aspergillus predicted time to 
ABX in multivariate analyses
We first devised a multivariate regression model (Table 2) for time 
to ABX which incorporated age, F508del-CFTR homozygosity, 
CFRD, FEV1%, and MDRPA and MRSA sputum status. In this 
model, every year of life lived by the 54 subjects was associated 
with a mean increase in time to ABX of 6.4 days. Model 1 explained 
32% of the variation in time to ABX (p = 0.003). Body mass index 
and FEV1% could not be simultaneously introduced into the 
model because of multicollinearity. Model 2 added Aspergillus in 
forward stepwise fashion. In model 2, age had the same effect as 
model 1 (b = 6.4, p = 0.001), but Aspergillus was not contributory. 
The variation in time to ABX accounted for by model 2 was 36% 
(p = 0.0003). Model 3 added serum iron to model 2 in forward 
stepwise fashion and accounted for 48% of variation in time to 
ABX with three significant terms. An increase in serum iron 
of 1 mcg/dL was associated with an increase in time to ABX of 
1.4 days. Model 3 revealed that subjects who were positive for 
Aspergillus received ABX an average of 61.7 days earlier than 
those who were not infected. Age was retained as statistically 
significant covariate in the final model, with each of life lived 
being associated with a 5.8 day increase in time to ABX.
Discussion
The primary objective of this study was to determine if a single 
serum iron measurement in CF adults significantly explained 
subsequent time to ABX. We were interested in this question 
because we had previously observed that CF patients with worse 
lung function and more severe malnutrition, features that could 
plausibly increase their chances of receiving ABX, also generally 
Factor Subjects (% of cohort) Mean days (SD) Mean difference (95% CI) p-Value
BMI (kg/m2)
  ≥25.0 (referent) 11 (20) 163.0 (146.2) – –
  18.1–24.9 35 (65) 114.9 (108.6) −48.1 (−34.3, 130.4) 0.25
  ≤18.0 8 (15) 45.5 (28.6) −117.5 (−228.9, −6.1) 0.04
FEV1%
  ≥60 (referent) 20 (37) 111.3 (99.4) – –
  41–59 17 (31.5) 144.9 (136.6) 33.6 (−112.6, 45.3) 0.39
  ≤40 17 (31.5) 87.7 (103.1) −23.7 − 91.3, 44.0) 0.48
Hemoglobin (g/dL)
  ≥13.0 (referent) 25 (46) 120.8 (129.3) – –
  12.9–10.1 22 (41) 125.4 (109.8) 4.6 (−66.4, 75.6) 0.90
  ≤10.0 7 (13) 57.6 (25.0) −63.2 (−164.6, 38.3) 0.21
F508del-CFTR homozygote
  No (referent) 24 (44) 124.5 (100.0) −18.1 (−80.9, 44.8) 0.57
  Yes 30 (56) 106.4 (124.6)
Sex
  Male (referent) 26 (48) 111.1 (129.0) 6.4 (−56.3, 69.1) 0.84
  Female 28 (52) 117.5 (99.6)
CFRD
  No (referent) 24 (44) 151.7 (140.4) −67.1 (−127.3, −6.9) 0.03
  Yes 30 (56) 84.6 (76.2)
Sputum MDRPA
  No (referent) 29 (54) 134.0 (124.9) −42.2 (−104.0, 19.5) 0.18
  Yes 25 (46) 91.8 (96.5)
Sputum MRSA
  No (referent) 45 (83) 107.4 (111.3) 42.4 (−40.8, 125.6) 0.31
  Yes 9 (17) 149.8 (125.6)
Sputum Aspergillus
  No (referent) 38 (70) 133.7 (126.6) −64.9 (−131.1, 1.3) 0.05
  Yes 16 (30) 68.8 (54.2)
CFRD = CF-related diabetes; BMI = body mass index; FEV1% = percent-predicted forced expiratory volume in 1 second; MDRPA = multidrug-resistant Pseudomonas 
 aeruginosa; MRSA = methicillin-resistant Staphylococcus aureus; WBC = white blood cell count. Data are presented as mean ± standard deviation.
Table 1. Clinical, microbiological, and biochemical characteristics of the study population.
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had lower circulating iron levels than healthier patients.22 
Moreover, we have found that serum concentrations of IL-6 
and hepcidin-25, two humoral mediators that lower blood iron 
content21 but are not readily quantifiable by clinical laboratories, 
are reduced by ABX, leading to relative improvements in serum 
iron.15 In the current study, we identified a significant linear 
relationship between time to ABX and serum iron (Figure 1A) 
and that serum iron contributed uniquely to a multivariate linear 
regression model describing variation in time to ABX (Table 2). 
We also noted that age and sputum positivity for Aspergillus were 
significant covariates in this model.
The aforementioned relationships between serum iron and 
time to ABX suggest that this parameter varies with the health 
status of CF patients, perhaps under the influence of hepcidin-25.28 
Whether and to what extent serum iron levels fall during the onset 
of PEx are not yet known. However, the end-stage CF lung is replete 
with iron and associated binding proteins, such as hemoglobin 
and ferritin.29 Thus, iron appears to accumulate in the lungs of CF 
patients as they age. If airway bleeding allows hemoglobin-bound 
iron to enter the CF lung during the earliest phases of PEx, this 
sequence might explain the shorter time to ABX in subjects with 
lower serum iron levels (Figure 1A). Further studies are needed to 
characterize the clinical ramifications of airway bleeding, including 
its potential contribution to the development of PEx.
This is the second study to show that Aspergillus infection is 
associated with PEx (Table 2), which is noteworthy because fungi 
are not routinely targeted for treatment, except in cases of allergic 
bronchopulmonary aspergillosis (ABPA).30 Without adjusting for 
FEV1% (which our study suggests is not necessary), Amin et al.6 
calculated a relative risk of 1.94 for PEx necessitating hospital 
admission among CF children with ≥2 Aspergillus-positive 
sputum cultures in the same year compared to those without this 
finding. In a young cohort (mean age: 17.2±9.2 years), Milla et al.31 
noted that older age but not recovery of Aspergillus from sputum 
more completely accounted for variation in negative outcomes. 
The prevalence of Aspergillus infection in our study (29.1%) 
was higher than that (12.4%) reported by Milla et al.,31 perhaps 
offering an explanation for this discordant finding. Regardless, 
the clinical ramifications of incident and prevalent Aspergillus 
airway infection in CF patients warrant further investigation.
Increasing age had a seemingly protective effect against 
antibiotic use (Figure 1B). Block et al.5 prospectively followed 
249 adult and adolescent CF patients who were infected by 
multidrug resistant bacteria for up to 4.5 years. Applying Fuchs 
criteria,32 these authors defined PEx as “an acute exacerbation 
of pulmonary symptoms that, in the opinion of the patient’s CF 
physician, was severe enough to require intravenous antibiotics.” 
Similar to our observation that younger patients were at higher 
risk of receiving antibiotics (Figure 1B), Block et al.5 noted that 
older age was independently associated with lower PEx risk, both 
in a Cox proportional-hazards model (HR 0.98, p = 0.03) and a 
multivariate logistic regression model of factors predicting PEx 
during the first year of follow-up (OR 0.93, p = 0.002).
This phenomenon has not been explained, but it might 
reflect an influence of patient age on decision making by CF 
care providers. Kraynack et al.9 surveyed CF centers using a 
series of vignettes and showed that even modest variations in 
clinical presentation substantially impacted antibiotic treatment 
decisions. One might also postulate that younger CF patients 
are more likely than older ones to access the healthcare system, 
perhaps because of more concerted advocacy from caregivers, 
fewer lifestyle responsibilities, and/or more frequent exposure 
to PEx triggers, including respiratory viruses.33 However, the 
mean age of subjects with PEx in our study was 29.1±8.8 years 
and was 30.1±13.8 years in that of Block et al.,5 diminishing the 
likelihood of these possibilities. Having affirmed that age alone 
somehow modifies risk of antibiotic use, we feel that contributory 
factors in adults and children should be sought and contrasted.
We acknowledge several limitations to our study. First, given 
its retrospective nature, we cannot exclude the possibility that 
subjects obtained antibiotics outside our CF center. This could 
confound our analyses because antibiotics increase serum iron 
levels,15 and we would not have known exactly when they were 
prescribed relative to data collection. By only including data from 
subjects who were in their usual state of health, we attempted 
to minimize the effects of antecedent antibiotic exposure on 
parameters of interest. However, 12 of 54 subjects (22%) had 
recently completed antibiotic courses. Because it is not yet known 
how rapidly and to what extent serum iron levels fall between 
antibiotic courses, we cannot explain how this subset might have 
influenced our calculations, except to offer that their symptoms 
may have waxed and waned more frequently, thus predisposing 
them to be treated with antibiotics more often.
Second, it is not yet known how inhaled antibiotics and 
macrolide antibiotics affect iron homeostasis in CF patients. 
Participants in the current study had been prescribed these classes 
of medications, but our models for time to ABX do not account 
for their use because we could not be completely confident about 
treatment adherence and documentation of their use.
Third, our work reflects the practice patterns of a single CF 
center. Although we could tell from the electronic health record 
when subjects were prescribed antibiotics, we cannot make 
any inferences about the clinical rationale behind their use and 
whether knowledge of serum iron or other attributes influenced 
Factor Model 1 Model 2 (Model 1 + Aspergillus) Model 3 (Model 2 + Serum Iron)
a 95% CI p-Value a 95% CI p-Value a 95% CI p-Value
Age 6.4 3.0, 9.8 0.0004 6.4 3.1, 9.7 0.001 5.8 2.9, 8.9 0.0003
CFRD −58.5 −113.8, −3.2 0.04 −47.3 −102.9, 8.3 0.09 – – –
MRSA 62.8 −11.5, 137.2 0.09 67.2 −5.8, 140.1 0.07 – – –
Aspergillus – – – −53.2 −113.6, 7.1 0.08 −61.7 −115.6, −7.7 0.03
Serum iron – – – – – – 1.4 0.6, 2.1 0.0006
β = coefficient; CI = confidence interval.
Table 2. Parameter estimates for predictors of time to ABX from multivariate linear regression models incorporating data from all subjects (n = 54).
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the decision making process. Despite the limited size of our cohort, 
it was similar in many ways to larger CF patient populations. 
However, the lower burden of MRSA34,35 and higher prevalence of 
MDRPA36 in our study are idiosyncrasies that might affect not only 
PEx frequency but also trends in biomarkers of iron homeostasis.
Finally, we were unable to report herein whether serum 
hepcidin-25 alone predicted variation in time to ABX. The cost 
associated with performance of the assay was prohibitive. As this 
was a retrospective study, we did not have archived serum from 
all 54 subjects. This would have been necessary to appropriately 
introduce serum hepcidin-25 into the multivariate models (Table 2).
Conclusion
In summary, we demonstrate that serum iron, age, and sputum 
Aspergillus positivity are factors associated with time to ABX in CF 
and may be useful in determining the risk that a patient will soon 
require antibiotics. Paradigms for risk stratification and risk factor 
modification have been described for acute coronary syndromes,37 
acute kidney injury,38 and acute pulmonary embolism39 but are 
not yet defined for PEx. Devising the most useful paradigm for 
PEx might require, as our data suggest, using multiple parameters 
to better explain variation in outcomes like antibiotic use. This 
approach also addresses the need for individualized treatment 
strategies for CF patients.
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